Methicillin‐resistenter Staphylococcus aureus (MRSA) in chronischen Wunden: Therapeutische Optionen und Perspektiven

Abstract

The contamination of chronic wounds with Methicillin-resistant Staphylococcus aureus (MRSA) represents a world-wide increasing problem. Although it is still unclear whether bacterial contamination is a relevant factor for delayed wound-healing, verification of MRSA contamination has significant logistic consequences for the medical institution as well as for the patient. In particular, if MRSA contamination progresses towards a systemic infection, options for antibiotic therapy are greatly limited. In this article, we discuss current therapeutic standards and potential alternatives for eradication of MRSA. There is evident need for effective, novel approaches for elimination of MRSA from chronic wounds that avoid the development of bacterial resistance; otherwise therapeutic alternatives for antibacterial treatment of chronic wounds will become more limited.

Influence of human wound exudate on the bactericidal efficacy of antiseptic agents in quantitative suspension tests on the basis of European Standards (DIN EN 13727)

“…Specifically chronic wounds are often colonised by a pool of different pathogens, promoting the formation of drug‐resistant biofilms and delaying wound healing . Furthermore, methicillin‐resistant Staphylococcus aureus (MRSA) have been found to be increasingly present in chronic wounds substantially complicating their management . Antimicrobial antiseptics are particularly suitable for eliminating these disturbing factors for wound healing.…”